IMMUTEP LTD/S (NASDAQ:IMMP) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of IMMUTEP LTD/S (NASDAQ:IMMP) from a hold rating to a buy rating in a report published on Thursday, ValuEngine reports.

Separately, Maxim Group restated a buy rating and issued a $7.00 price target on shares of IMMUTEP LTD/S in a research report on Wednesday, May 1st.

Shares of NASDAQ IMMP traded down $0.04 during mid-day trading on Thursday, reaching $1.45. The company had a trading volume of 300 shares, compared to its average volume of 30,446. IMMUTEP LTD/S has a one year low of $1.48 and a one year high of $4.21. The firm has a market cap of $50.37 million, a price-to-earnings ratio of -3.82 and a beta of 1.45. The company has a 50-day moving average price of $1.73.

An institutional investor recently raised its position in IMMUTEP LTD/S stock. Deutsche Bank AG increased its holdings in shares of IMMUTEP LTD/S (NASDAQ:IMMP) by 23.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 100,040 shares of the biotechnology company’s stock after purchasing an additional 18,800 shares during the quarter. Deutsche Bank AG owned 0.37% of IMMUTEP LTD/S worth $184,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 2.15% of the company’s stock.

IMMUTEP LTD/S Company Profile

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells.

Read More: Stock Split

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IMMUTEP LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMUTEP LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.